Merck

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
>
Registration as it was on 13 Nov 2019
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 55120759781-59

Overview

Lobbying Costs

980,442€

Financial year: Jan 2018 - Dec 2018

Lobbyists (Full time equivalent)

2.75 Fte (5)

Lobbyists with EP accreditation

5

High-level Commission meetings

15

Lobbying Costs over the years

  • Info

    Merck

    EU Transparency Register

    49654992078-52 First registered on 28 Jul 2009

    Goals / Remit

    Merck, a leading science and technology company, generated total revenues of € 14,836 million in 2018 with its divisions Healthcare, Performance Materials and Life Science. More than 52,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are the United States and Canada. Here we operate as EMD Serono in the Biopharma business, MilliporeSigma in the Life Science business, and as EMD Performance Materials in the Performance Materials business.

    Main EU files targeted

    Industrial Policy Strategy, Data Protection Directive, Cross Border Directive, TTIP, Emission Trading System (ETS), Energy Efficiancy, Digitalization Strategy, Global Health Policy, Brexit

    Address

    Head Office
    Frankfurter Strasse, 250
    Darmstadt 64293
    GERMANY
  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    100%1
    50%3
    25%1

    Lobbyists (Full time equivalent)

    2.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    5 accreditations were / are live (in bold) for the selected state of 13 Nov 2019

    Name Start date End Date
    Ms Sabrina CONTI 24 Jan 2024 23 Jan 2025
    Ms Ana POLANCO ALVAREZ 24 Jan 2024 23 Jan 2025
    Ms Elisa DIAZ MARTINEZ 06 Dec 2023 05 Dec 2024
    Mr Franjo CAIC 14 Oct 2023 11 Oct 2024
    Mr Jean Paul Andre EL AHL 14 Sep 2023 13 Sep 2024
    Ms Maike BECKER-KRÜGER 10 May 2023 09 May 2024
    Ms Ana POLANCO ALVAREZ 01 Mar 2023 24 Jan 2024
    Ms Sabrina CONTI 19 Jan 2023 18 Jan 2024
    Mr Tim MERTENS 14 Dec 2022 10 May 2023
    Mr Franjo CAIC 29 Oct 2022 14 Oct 2023
    Ms Liesbet DENDAS 06 Jul 2022 06 Jul 2023
    Mr Jean Paul Andre EL AHL 06 Jul 2022 06 Jul 2023
    Mr Tim MERTENS 09 Oct 2021 08 Oct 2022
    Mr Franjo CAIC 08 Oct 2021 08 Oct 2022
    Mr Jean Paul Andre EL AHL 25 Aug 2021 06 Jul 2022
    Ms Anne PAPIN DI POMPEO 27 Jul 2021 27 Jul 2022
    Mr Hugh Thomas PULLEN 20 Feb 2020 20 Feb 2021
    Ms Anne PAPIN DI POMPEO 20 Feb 2020 20 Feb 2021
    Ms Mihaela Militaru 20 Feb 2020 20 Feb 2021
    Ms Irene Maria DE CARA 20 Feb 2020 20 Feb 2021
    Ms Vanessa POTT 20 Feb 2020 20 Feb 2021
    Mr Tim MERTENS 19 Nov 2019 01 Dec 2020
    Ms Isabel VLACHOPOULOU KLINNERT 27 Mar 2019 27 Mar 2020
    Ms Anne PAPIN DI POMPEO 16 Jan 2019 16 Jan 2020
    Ms Mihaela Militaru 16 Jan 2019 16 Jan 2020
    Mr Hugh Thomas PULLEN 08 Jan 2019 01 Jan 2020
    Ms Irene Maria DE CARA 08 Jan 2019 01 Jan 2020
    Ms Vanessa POTT 04 Oct 2018 01 Nov 2019
    Mr Franjo CAIC 28 Mar 2018 28 Mar 2019
    Ms Isabel VLACHOPOULOU KLINNERT 15 Mar 2018 15 Mar 2019
    Mr Hugh Thomas PULLEN 25 Nov 2017 24 Nov 2018
    Ms Mihaela Militaru 25 Nov 2017 24 Nov 2018
    Ms Irene Maria DE CARA 25 Nov 2017 24 Nov 2018
    Ms Anne PAPIN DI POMPEO 31 Aug 2017 31 Aug 2018
    Ms Vanessa POTT 20 Jul 2017 20 Jul 2018
    Ms Sara-Andrada Dumitrana 22 Mar 2017 21 Mar 2018
    Mr Franjo CAIC 22 Mar 2017 21 Mar 2018
    Mr Hugh Thomas PULLEN 09 Nov 2016 09 Nov 2017
    Ms Irene Maria DE CARA 04 Nov 2016 03 Nov 2017
    Ms Mihaela Militaru 28 Oct 2016 28 Oct 2017
    Mr Marcel Daniels 19 Jul 2016 08 Jul 2017
    Ms Sara-Andrada Dumitrana 16 Feb 2016 04 Feb 2017
    Mr Marcel Daniels 17 Jun 2015 15 Jun 2016
    Mr Hugh Thomas PULLEN 17 Jun 2015 15 Jun 2016
    Ms Sara-Andrada Dumitrana 04 Nov 2014 30 Oct 2015
    Mrs Sara-Andrada Dumitrana 04 Nov 2014 27 Jan 2015
    Mr Hugh Thomas PULLEN 07 Jun 2014 05 Jun 2015
    Mr Marcel Daniels 06 May 2014 15 Apr 2015

    Complementary Information

    8 more employees with a time coverage of <10%
    seven employees in total with an EP Pass

    Person in charge of EU relations

    Mr Tim Mertens (Head of Corporate and Government Relations Brussels)

    Person with legal responsibility

    Mr Dr. Stefan Oschmann (Chairman of the Executive Board, CEO of Merck)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Merck is a member of CEFIC (EU), EFPIA (EU), EuropaBio (EU), EBE - European Biopharmaceutical Enterprises (EU), MedTech Europe (EU), VCI (DE), VfA (DE) and the British Chamber of Commerce in Belgium.

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2018 - Dec 2018

    Lobbying costs for closed financial year

    980,442€

    Other financial info

    Absolute value: € 980 442.98

    The costs of Merck activities for the year 2018 include:

    1) staff costs based on the full-time equivalents of employee time devoted to activities falling under the Register;

    2) percentage of the overall costs of running an office in Brussels, based on the proportion of employee time spent on these activities;

    3) payment to third parties (e.g. fees for external agencies* support) and membership and related fees for joining relevant associations, for their activities falling under the Register.

    * For certain external agencies, it was not possible to fully separate activities falling under the scope of the transparency register from those taking place in other countries. In the interests of transparency, the full amounts have been included in those cases.

    This estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Merck would like to indicate that all entries have been made in line with the greatest possible transparency and are periodically being updated as required.




  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    Activities in the policy areas of Pharma and Health legislation, Energy and Climate, Environment and Chemicals legislations, Biotechnology, Taxation, Research and Development as well as the Brexit process.
    Merck is committed to work in partnerships with the European institutions to support policies and actions that facilitates patient access to treatments for unmet medical needs, especially chronic and rare diseases, as well as aspects supporting European R&D in innovative healthcare technologies.

  • Meetings

    Meetings

    15 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 05 Jun 2023 Location Brussels
      Subject Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Zaneta Vegnere (Cabinet member)
      • Elina Melngaile (Cabinet member)
      Other Lobbyists
    • Date 18 Feb 2023 Location München
      Subject Review of pharmaceutical legislation. TRIPS waiver.
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Valdis Dombrovskis (Executive Vice-President)
    • Date 18 Jan 2023 Location Davos, Switzerland
      Subject Deep tech innovation for life sciences & biological components EU Innovation Agenda EU Mission on cancer R&I for health EU Research on semi-conductors
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Digital Economy and Society
      Attending
      • Mariya Gabriel (Commissioner)
    • Date 18 Jan 2023 Location Davos, Switzerland
      Subject Deep tech innovation for life sciences & biological components EU Innovation Agenda EU Mission on cancer R&I for health EU Research on semi-conductors
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Innovation and Youth
      Attending
      • Mariya Gabriel (Commissioner)
    • Date 08 Nov 2022 Location Brussels
      Subject Share initiatives and explore ways of collaboration and synergy
      Cabinet Cabinet of Commissioner Helena Dalli
      Portfolio Equality
      Attending
      • Lesia Radelicki (Cabinet member)
    • Date 04 Apr 2022 Location virtual
      Subject Current issues such as the transformation of the European economy, and how the Chemical and Pharmaceutical industry
      Cabinet Cabinet of Commissioner Paolo Gentiloni
      Portfolio Economy
      Attending
      • Alienor Margerit (Cabinet member)
    • Date 30 Nov 2021 Location Brussels
      Subject Pharma Strategy
      Cabinet Cabinet of Vice-President Margaritis Schinas
      Portfolio Promoting the European Way of Life
      Attending
      • Margaritis Schinas (Vice-President)
      • Maria Luisa Llano Cardenal (Cabinet member)
    • Date 26 Oct 2021 Location Brussels
      Subject Pharmaceutical sector – trade related issues
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Caroline Boeshertz (Cabinet member)
      • Kevin Keary (Cabinet member)
      • Elina Melngaile (Cabinet member)
      Other Lobbyists
    • Date 03 Sep 2021 Location Brussels
      Subject FF55 and the pharmaceutical industry
      DG Climate Action
      Attending
      • Mauro Raffaele Petriccione (Director-General)
    • Date 12 Apr 2021 Location Brussels
      Subject Global supply chains for disposables
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 02 Mar 2021 Location videoconference
      Subject Vaccine production
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      Other Lobbyists
    • Date 29 May 2018 Location Brussels
      Subject Preparation of the IMI 10th Anniversary
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 14 Nov 2017 Location Strasbourg
      Subject Circular economy, priorities of Juncker Commission and AMR (Antimicrobial Resistance) Action Plan
      DG Communication
      Attending
      • Timo Pesonen (Director-General)
    • Date 23 Nov 2016 Location Brussels
      Subject EPFIA's Priorities
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 22 Apr 2016 Location Brussels
      Subject HTA
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Annika Nowak (Cabinet member)
Download this datacard